Overview:

The biotech industry is the driver of innovation in new treatment. Nevertheless, there is no clear data on the success rates of Biotech companies in drug development.

This report summarized the success rates of 211 publicly traded biotech companies with more than 1,500 drugs in development fort he period 2002 - 2009. The success rates are discussed per disease group and put into context to existing data on drug development attrition rates. The report also gives on outlook on the resulting implications for stakeholders of the biotech industry based on the identified drawbacks in the current biotech business model.

1 Introduction
1.1 Why a study on success rates of biotech companies?
1.2 What are success rates?
1.3 The role of success rates
1.4 Are success rates of biotech companies different?

2 Methods
2.1 Origin of Data
2.2 Difference between FDA and EMEA
2.3 Time frame
2.4 Success rates per molecule vs. success rates per indication
2.5 Companies of the sample

3 Results
3.1 Reporting of success and failure
3.2 Distribution of sample over disease groups
3.3 Overall biotech success rates (IND to approval)
3.4 Disease group specific overall success rates (IND to approval)
3.5 Number of projects in different disease groups
3.6 Disease group specific Success Rates
3.6.1 Cancer (471 projects)
3.6.2 Neurology (157 projects)
3.6.3 Infectious (56 projects)
3.6.4 Inflammation (127 projects)
3.6.5 Cardiovascular (85 projects)
3.6.6 Pain management (75 projects)
3.6.7 Dermatology (31 projects)
3.6.8 Endocrinology (27 projects)
3.6.9 Metabolic (66 projects)
3.6.10 Genitourinary (38 projects)
3.6.11 Hematology (28 projects)
3.6.12 Gastrointestinal (28 projects)

4 Discussion
4.1 Success Rates in Biotech (Avance) and Pharma (Kola, Landis)
4.2 Difference in cancer
4.3 Difference in Neurology
4.4 Difference in Infectious Diseases
4.5 Difference in Inflammation
4.6 Difference in Cardiovascula
4.7 Biotech has more late stage failures
4.8 Case Study: Arpida
4.9 Biotech does not abandon low potential drugs

5 Conclusion